Influence of formulation variables on miconazole nitrate-loaded lipid based nanocarrier for topical delivery
Autor: | Shadeed Gad, Mamdouh M. Ghorab, El-Sayed Khafagy, Passant Mohamed Al-maghrabi |
---|---|
Rok vydání: | 2019 |
Předmět: |
Azoles
Antifungal Agents Surface Properties Dispersity 02 engineering and technology Microbial Sensitivity Tests 01 natural sciences Colloid and Surface Chemistry Drug Delivery Systems 0103 physical sciences Solid lipid nanoparticle Candida albicans Zeta potential Physical and Theoretical Chemistry Particle Size Drug Carriers Nitrates 010304 chemical physics biology Chemistry Surfaces and Interfaces General Medicine 021001 nanoscience & nanotechnology biology.organism_classification Controlled release Lipids Toxicity Miconazole Nitrate Nanoparticles Particle size 0210 nano-technology Biotechnology Nuclear chemistry |
Zdroj: | Colloids and surfaces. B, Biointerfaces. 193 |
ISSN: | 1873-4367 |
Popis: | The purpose of this study was to develop miconazole nitrate (MN) based solid lipid nano-carrier formulae for topical delivery to enhance its antifungal effectiveness. Miconazole nitrate loaded Solid lipid nanoparticles (MN-SLNs) were formulated using a high shear homogenization technique characterized by particle size, polydispersity index (PI), trapping efficiency (EE percent), drug loading (DL percent) and zeta potential (ZP) characteristics. Furthermore, the optimized formulae were investigated for in-vitro release, ex-vivo study, skin toxicity test, and antifungal activity. With a particle size range of 244.2 ± 27.2 nm to 493.6 ± 35.3 nm, the selected MN-SLNs were spherical shaped. A high EE product percentage ranging from 79.38 ± 2.35 percent to 95.92 ± 6.12 percent and Zeta potential ZP values ranging from-21.6 ± 7.05 mV to-31.4 ± 6.84 mV suggesting strong stability was achieved. A controlled release of MN from the SLNs up to 48 h was shown in-vitro release study. The ex-vivo study showed that the selected MN-SLN (F4) mixture exhibited higher MN flux in the skin than a 1% MN solution. Moreover, selected MN-SLN (F4) has demonstrated a higher zone of inhibition against Candida albicans than a simple drug solution. MN-SLN (F4) had the lowest toxicity value for the skin. Besides, the MN-SLNs (F4) substantially reported antifungal activity with the least histopathological improvements compared to MN-solution utilizing immune-suppressing albino rats with induced candidiasis fungal infection. It can be fulfilled that SLNs can be acquired as a promising carrier for topical delivery of poorly soluble MN. |
Databáze: | OpenAIRE |
Externí odkaz: |